REVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
REVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0. Revelation Biosciences's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2025-03-15), Revelation Biosciences's share price is $3.45. Revelation Biosciences's Median PS Value is $0.00. Therefore, Revelation Biosciences's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Revelation Biosciences's Median PS Value or its related term are showing as below:
The historical data trend for Revelation Biosciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Median PS Value | - | - | - | - | - |
Revelation Biosciences Quarterly Data | ||||||||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Revelation Biosciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's Price-to-Median-PS-Value falls into.
Revelation Biosciences's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences (NAS:REVB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Revelation Biosciences's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 3.45 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Revelation Biosciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
George F Tidmarsh | director, 10 percent owner | |
Lakhmir S Chawla | director | 1960 KIRBY ROAD, MCLEAN VA 22101 |
Axa Im Prime Impact Gp S.a.r.l | other: Former 10% owner | 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453 |
Axa Im Prime Impact Master Fund I Sca Sicav-raif | other: Former 10% Owner | 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453 |
Axa Investment Managers S.a. | other: Former 10% owner | 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800 |
Axa Investment Managers Paris | other: Former 10% owner | 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800 |
Axa Investment Managers Uk Ltd | other: Former 10% owner | 22 BISHOPGATE, LONDON X0 EC2M 3XJ |
S.a. Axa | other: Former 10% owner | 25 AVENUE MATIGNON, PARIS I0 75008 |
Jess Roper | director | 5555 OBERLIN DRIVE, SAN DIEGO CA 92121 |
James Rolke | director, officer: Chief Executive Officer | 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121 |
Curt H Labelle | director | C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011 |
Jennifer Carver | director | 725 NEWPORT STREET, DENVER CO 80220 |
Zygmont Chester Stanley Iii | officer: Chief Financial Officer | 3322 MILLIKIN AVE, SAN DIEGO CA 92122 |
Lawrence Feis | 10 percent owner | 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611 |
Feis Equities Llc | 10 percent owner | 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606 |
From GuruFocus
By Business Wire • 11-08-2024
By Business Wire • 10-12-2023
By Business Wire • 01-23-2024
By Business Wire • 01-24-2025
By Business Wire • 01-21-2025
By Business Wire • 06-24-2024
By Business Wire • 01-06-2025
By Business Wire Business Wire • 06-12-2023
By Business Wire • 03-12-2024
By Business Wire • 08-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.